Just weeks after reporting poor Phase II data on a congestive heart failure drug, Cardiome Pharma Corp. unveiled plans to expand its portfolio by acquiring Artesian Therapeutics Inc. in a deal that could be worth $64 million. But right now, the buyout won't affect the bottom line, as the final value is contingent on the clinical success of two investigational drugs. (BioWorld Today) Read More
